Analyzing Bristol-Myers Squibb’s Oncology Portfolio
Bristol-Myers Squibb’s (BMY) oncology portfolio includes its Empliciti, Opdivo, Sprycel, and Yervoy products.
Interested in BIIB? Don't miss the next report.
Receive e-mail alerts for new research on BIIB
The chart above shows revenues for the company’s oncology products over the last few quarters.
Empliciti is a new drug approved for use in combination with Celgene’s (CELG) Revlimid and dexamethasone in previously treated patients with multiple myeloma. It reported 62% growth in revenues to $55 million in 2Q17, compared to $34 million in 2Q16.
Opdivo is a human PD-1 blocking antibody approved for the treatment of various forms of cancer. It reported 42% growth in revenues to $1.19 billion in 2Q17, compared to revenues of $840 million in 2Q16. We discuss Opdivo’s performance and recent developments later in this series!
Sprycel is an oral inhibitor used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia as well as Philadelphia chromosome-positive acute lymphoblastic leukemiar. It reported 12% growth in revenues to $506 million in 2Q17, compared to $451 million in 2Q16. The growth was driven by increased demand for the drug in US markets.
Yervoy, a monoclonal antibody, is approved for the treatment of certain types of melanoma. Yervoy reported 34% growth in revenues to $322 million in 2Q17, compared to $241 million in 2Q16. The growth was driven by an increase in sales in US markets, offset by weaker sales across international markets due to competition.
To divest company-specific risks, investors can consider ETFs like the Fidelity MSCI Health Care ETF (FHLC), which invests 2.8% of its total assets in Bristol-Myers Squibb (BMY). FHLC also invests 9.7% in Johnson & Johnson (JNJ), 3.0% in Medtronic (MDT), and 1.9% in Biogen (BIIB).